September 23, 2020
MSD K.K., the Japan arm of US Merck, said on September 18 that it has withdrawn an application for its PD-1 inhibitor Keytruda (pembrolizumab) targeting a frontline indication for gastric cancer following discussions with local regulatory authorities. The drug maker...read more